1887

Abstract

complex (MABC) is an infectious agent associated with macrolide resistance and treatment failure.

Despite drug-susceptibility testing for MABC isolates including clarithromycin (CAM), long-term treatment with azithromycin (AZM) for MABC disease is recommended.

We compared phenotypic and genotypic resistance to AZM and CAM in clinical isolates and evaluated the accumulation of intrinsic macrolide resistance (AIM) and morphological changes by macrolides exposure.

Forty-nine isolates were characterized regarding (41) sequevars. Sequencing data were compared to the nucleotide sequence of and . The AIM MIC was performed in three reference strains and 15 isolates were randomized [each set of five isolates with subsp. (MAA) T28, MAA C28 and subsp. (MAM)].

The 49 isolates were distributed as 24 MAA T28, 5 MAA C28 and 20 MAM. The MIC values to CAM at day 3 in MAA T28, C28 and MAM were 1, 0.12 and 0.12 µg ml, while those at day 14 were 32, 0.5 and 0.12 µg ml, respectively. The AZM-MIC values at day 3 of the above isolates were 4, 0.25 and 0.5 µg ml, while those at day 14 were >64, 0.5 and 0.5 µg ml, respectively. Neither mutations in of MAA T28 with acquired resistance nor deletions in of MAA T28 without inducible resistance were observed . For AIM MIC, MAA T28 showed that the time-to-detection of AZM resistance was significantly faster over that of CAM (<0.05). Morphological changes were not determined in all isolates.

Our findings did not support the suggestion for the preferential use of AZM for, at least, MAA T28 disease due to the high-level MIC value and the increased AIM. The long duration of AZM-based treatment eventually may favour the emergence of isolates with a high-level of intrinsic resistance.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001326
2021-02-11
2021-03-02
Loading full text...

Full text loading...

References

  1. Lee M-R, Sheng W-H, Hung C-C, Yu C-J, Lee L-N et al. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis 2015; 21: 1638 1646 [CrossRef] [PubMed]
    [Google Scholar]
  2. Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leão SC et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol 2016; 66: 4471 4479 [CrossRef] [PubMed]
    [Google Scholar]
  3. Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae . Antimicrob Agents Chemother 2009; 53: 1367 1376 [CrossRef] [PubMed]
    [Google Scholar]
  4. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol 2015; 53: 1211 1215 [CrossRef] [PubMed]
    [Google Scholar]
  5. Yoshida S, Tsuyuguchi K, Suzuki K, Tomita M, Okada M et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. Int J Antimicrob Agents 2013; 42: 226 231 [CrossRef] [PubMed]
    [Google Scholar]
  6. Jeong SH, Kim S-Y, Huh HJ, Ki C-S, Lee NY et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Int J Infect Dis 2017; 60: 49 56 [CrossRef] [PubMed]
    [Google Scholar]
  7. Koh W-J, Jeong B-H, Kim S-Y, Jeon K, Park KU et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 2017; 64: 309 316 [CrossRef] [PubMed]
    [Google Scholar]
  8. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T. British thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017 72
    [Google Scholar]
  9. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis 2020; 71: e1 e36 [CrossRef] [PubMed]
    [Google Scholar]
  10. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019; 54: 1801991 11 07 2019 [CrossRef] [PubMed]
    [Google Scholar]
  11. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM et al. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes Clinical and Laboratory Standards Institute; 2018 p M62
    [Google Scholar]
  12. Maurer FP, Castelberg C, Quiblier C, Böttger EC, Somoskövi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus . J Antimicrob Chemother 2014; 69: 1559 1563 [CrossRef] [PubMed]
    [Google Scholar]
  13. Tsai S-H, Lai H-C, Hu S-T. Subinhibitory doses of aminoglycoside antibiotics induce changes in the phenotype of Mycobacterium abscessus . Antimicrob Agents Chemother 2015; 59: 6161 6169 [CrossRef] [PubMed]
    [Google Scholar]
  14. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes Clinical Laboratory Standards Institute; 2018
    [Google Scholar]
  15. Yoshida S, Tsuyuguchi K, Kobayashi T, Tomita M, Inoue Y et al. Discrepancies between the genotypes and phenotypes of clarithromycin-resistant Mycobacterium abscessus complex. Int J Tuberc Lung Dis 2018; 22: 413 418 [CrossRef] [PubMed]
    [Google Scholar]
  16. Mougari F, Bouziane F, Crockett F, Nessar R, Chau F et al. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother 2017; 61: 27 12 2016 [CrossRef] [PubMed]
    [Google Scholar]
  17. Pryjma M, Burian J, Kuchinski K, Thompson CJ. Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of Mycobacterium abscessus infections is mediated by the whiB7 gene. Antimicrob Agents Chemother 2017; 61: e01353 17 [CrossRef] [PubMed]
    [Google Scholar]
  18. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30: 2725 2729 [CrossRef] [PubMed]
    [Google Scholar]
  19. Choi G-E, Shin SJ, Won C-J, Min K-N, Oh T et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917 925 [CrossRef] [PubMed]
    [Google Scholar]
  20. Bastian S, Veziris N, Roux A-L, Brossier F, Gaillard J-L et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775 781 [CrossRef] [PubMed]
    [Google Scholar]
  21. Park J, Cho J, Lee C-H, Han SK, Yim J-J. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense . Clin Infect Dis 2017; 64: 301 308 [CrossRef] [PubMed]
    [Google Scholar]
  22. Guo Q, Chen J, Zhang S, Zou Y, Zhang Y et al. Efflux pumps contribute to intrinsic clarithromycin resistance in clinical, Mycobacterium abscessus isolates. Infect Drug Resist 2020; 13: 447 454 [CrossRef] [PubMed]
    [Google Scholar]
  23. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15: 149 161 [CrossRef] [PubMed]
    [Google Scholar]
  24. Hurst-Hess K, Rudra P, Ghosh P. Mycobacterium abscessus WhiB7 regulates a species-specific repertoire of genes to confer extreme antibiotic resistance. Antimicrob Agents Chemother 2017; 61: 24 10 2017 [CrossRef] [PubMed]
    [Google Scholar]
  25. Koh W-J, Jeon K, Lee NY, Kim B-J, Kook Y-H et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus . Am J Respir Crit Care Med 2011; 183: 405 410 [CrossRef] [PubMed]
    [Google Scholar]
  26. Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Front Microbiol 2018; 9: 2179 [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001326
Loading
/content/journal/jmm/10.1099/jmm.0.001326
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error